Do We Have a Winner? Advocating for SBRT in HCC Management

Amir H Safavi; Laura A Dawson; Aruz Mesci

doi:10.1016/j.ctro.2024.100740

Do We Have a Winner? Advocating for SBRT in HCC Management

Clin Transl Radiat Oncol. 2024 Feb 2:45:100740. doi: 10.1016/j.ctro.2024.100740. eCollection 2024 Mar.

Authors

Amir H Safavi¹, Laura A Dawson^{1

2}, Aruz Mesci^{1

2}

Affiliations

¹ Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
² Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

Abstract

•Stereotactic body radiotherapy (SBRT) is a safe and effective locoregional therapy for inoperable patients with HCC.•SBRT compares favorably with other local therapies in terms of local control, survival, morbidity, and cost-effectiveness.•SBRT should be considered and discussed in multidisciplinary management of appropriate HCC patients.•Advances in SBRT and novel combinations with systemic therapy may further widen the therapeutic index in HCC.

Keywords: Hepatocellular carcinoma; Locoregional therapies; Radiation Oncology; Stereotactic body radiotherapy.